Found: 67
Select item for more details and to access through your institution.
Activation of latent protease function of pro-hk2, but not pro-PSA, involves autoprocessing.
- Published in:
- Prostate, 2001, v. 48, n. 2, p. 122, doi. 10.1002/pros.1088
- By:
- Publication type:
- Article
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
- Published in:
- Prostate, 2001, v. 48, n. 1, p. 1, doi. 10.1002/pros.1075
- By:
- Publication type:
- Article
In Vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
- Published in:
- Prostate, 2000, v. 45, n. 1, p. 80, doi. 10.1002/1097-0045(20000915)45:1<80::AID-PROS10>3.0.CO;2-Q
- By:
- Publication type:
- Article
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells.
- Published in:
- Prostate, 2000, v. 43, n. 4, p. 303, doi. 10.1002/1097-0045(20000601)43:4<303::AID-PROS10>3.0.CO;2-V
- By:
- Publication type:
- Article
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
- Published in:
- Prostate, 1999, v. 39, n. 4, p. 269, doi. 10.1002/(SICI)1097-0045(19990601)39:4<269::AID-PROS7>3.0.CO;2-F
- By:
- Publication type:
- Article
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2.
- Published in:
- Prostate, 1999, v. 38, n. 1, p. 46, doi. 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9
- By:
- Publication type:
- Article
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
- Published in:
- Prostate, 1997, v. 33, n. 3, p. 201, doi. 10.1002/(SICI)1097-0045(19971101)33:3<201::AID-PROS9>3.0.CO;2-L
- By:
- Publication type:
- Article
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
- Published in:
- Prostate, 1996, v. 28, n. 4, p. 251, doi. 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G
- By:
- Publication type:
- Article
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 2, p. 97, doi. 10.1016/j.clgc.2021.08.001
- By:
- Publication type:
- Article
In Reply.
- Published in:
- Stem Cells Translational Medicine, 2019, v. 8, n. 7, p. 739, doi. 10.1002/sctm.19-0068
- By:
- Publication type:
- Article
A Phase I Study to Assess the Safety and Cancer‐Homing Ability of Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.
- Published in:
- Stem Cells Translational Medicine, 2019, v. 8, n. 5, p. 441, doi. 10.1002/sctm.18-0230
- By:
- Publication type:
- Article
Concise Review: Mesenchymal Stem Cell‐Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise.
- Published in:
- Stem Cells Translational Medicine, 2018, v. 7, n. 9, p. 651, doi. 10.1002/sctm.18-0024
- By:
- Publication type:
- Article
Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
- Published in:
- Proteins, 2009, v. 77, n. 4, p. 984, doi. 10.1002/prot.22524
- By:
- Publication type:
- Article
Mechanistic insights into the inhibition of prostate specific antigen by β-lactam class compounds.
- Published in:
- Proteins, 2008, v. 70, n. 4, p. 1416, doi. 10.1002/prot.21676
- By:
- Publication type:
- Article
Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2006, v. 91, n. 1, p. 79, doi. 10.1210/jc.2005-1882
- By:
- Publication type:
- Article
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
- Published in:
- 2006
- By:
- Publication type:
- journal article
A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 5, p. 376, doi. 10.1093/jnci/djk065
- By:
- Publication type:
- Article
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
- Published in:
- 2003
- By:
- Publication type:
- journal article
The association of sex steroid hormone concentrations with non‐alcoholic fatty liver disease and liver enzymes in US men.
- Published in:
- Liver International, 2021, v. 41, n. 2, p. 300, doi. 10.1111/liv.14652
- By:
- Publication type:
- Article
Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics.
- Published in:
- Molecules, 2021, v. 26, n. 24, p. 7469, doi. 10.3390/molecules26247469
- By:
- Publication type:
- Article
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 269, p. 1, doi. 10.1126/scitranslmed.3010563
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with 18F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPvL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup>F-DCFPyL PET/CT.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
- Published in:
- Prostate, 2020, v. 80, n. 5, p. 407, doi. 10.1002/pros.23955
- By:
- Publication type:
- Article
A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
- Published in:
- Prostate, 2019, v. 79, n. 14, p. 1597, doi. 10.1002/pros.23883
- By:
- Publication type:
- Article
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302.
- Published in:
- Prostate, 2019, v. 79, n. 8, p. 929, doi. 10.1002/pros.23798
- By:
- Publication type:
- Article
PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
- Published in:
- Prostate, 2018, v. 78, n. 11, p. 819, doi. 10.1002/pros.23539
- By:
- Publication type:
- Article
Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
- Published in:
- Prostate, 2017, v. 77, n. 8, p. 829, doi. 10.1002/pros.23323
- By:
- Publication type:
- Article
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
- Published in:
- Prostate, 2016, v. 76, n. 13, p. 1218, doi. 10.1002/pros.23209
- By:
- Publication type:
- Article
Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen.
- Published in:
- Prostate, 2016, v. 76, n. 13, p. 1203, doi. 10.1002/pros.23216
- By:
- Publication type:
- Article
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
- Published in:
- Prostate, 2016, v. 76, n. 8, p. 703, doi. 10.1002/pros.23162
- By:
- Publication type:
- Article
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
- Published in:
- Prostate, 2015, v. 75, n. 14, p. 1518, doi. 10.1002/pros.23024
- By:
- Publication type:
- Article
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2014, v. 74, n. 15, p. 1560, doi. 10.1002/pros.22874
- By:
- Publication type:
- Article
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
- Published in:
- Prostate, 2014, v. 74, n. 13, p. 1308, doi. 10.1002/pros.22847
- By:
- Publication type:
- Article
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.
- Published in:
- Prostate, 2012, v. 72, n. 14, p. 1491, doi. 10.1002/pros.22504
- By:
- Publication type:
- Article
Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.
- Published in:
- Prostate, 2012, v. 72, n. 11, p. 1233, doi. 10.1002/pros.22474
- By:
- Publication type:
- Article
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
- Published in:
- Prostate, 2011, v. 71, n. 15, p. 1595, doi. 10.1002/pros.21375
- By:
- Publication type:
- Article
Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
- Published in:
- Prostate, 2010, v. 70, n. 14, p. 1600, doi. 10.1002/pros.21196
- By:
- Publication type:
- Article
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
- Published in:
- Prostate, 2010, v. 70, n. 7, p. 788, doi. 10.1002/pros.21111
- By:
- Publication type:
- Article
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
- Published in:
- Prostate, 2007, v. 67, n. 3, p. 312, doi. 10.1002/pros.20531
- By:
- Publication type:
- Article
Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and humanSaurabh Aggarwal and Rebecca M. Ricklis contributed equally to this work.
- Published in:
- Prostate, 2006, v. 66, n. 9, p. 903, doi. 10.1002/pros.20413
- By:
- Publication type:
- Article